The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Equipped with a new CEO, Vor Bio is transitioning into an autoimmune player, leaving cell and gene therapy behind.

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

Several companies on the Wall Street have seen some Seeking Alpha analyst activity, including both upgrades and downgrades in ...

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...